Licensing opportunity
Researchers at the University of Neuchâtel, Switzerland, have developed a family of photodynamic compounds that can target tumour cells. The compounds, which are now available for licensing, comprise a porphyrin ring coordinated to arene-ruthenium units, offering, say the researchers, an easy functionalisation to customise various derivatives with defined properties.
The advantages of the compounds include high efficacy through combining the cytotoxic effects of ruthenium and porphyrin, high cytotoxicity in tuour cells, high cellular uptake and cytoplasmic accumulation into melanoma cells, and low cyctotoxicity to non-cancer cells. In vivo preclinical experiments are ongoing.
The researchers foresee potential applications in the diagnosis and treatment of cancer, pre-cancerous lesions, infectious diseases and inflammation and immune disorders.
Researchers at the University of Neuchâtel, Switzerland, have developed a family of photodynamic compounds that can target tumour cells. The compounds, which are now available for licensing, comprise a porphyrin ring coordinated to arene-ruthenium units, offering, say the researchers, an easy functionalisation to customise various derivatives with defined properties.
The advantages of the compounds include high efficacy through combining the cytotoxic effects of ruthenium and porphyrin, high cytotoxicity in tuour cells, high cellular uptake and cytoplasmic accumulation into melanoma cells, and low cyctotoxicity to non-cancer cells. In vivo preclinical experiments are ongoing.
The researchers foresee potential applications in the diagnosis and treatment of cancer, pre-cancerous lesions, infectious diseases and inflammation and immune disorders.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
